Six patients undergoing chronic hemodialysis and 10 patients with chronic renal insufficiency hospitalized for nondialytic therapy received 1.0 g of cephapirin sodium by the intravenous route. Cephapirin, 7-(pyrid-4-yl thioacetamido) cephalosporonate, is a new semisynthetic derivative of 7-aminocephalosporanic acid effective in vitro against gram-positive and gram-negative microorganisms. Concentrations of cephapirin necessary to inhibit Diplococcus pneumoniae, Mycobacterium tuberculosis (H37Rv), and Enterobacter sp. in vivo are less than those of cephalothin (3). The amount of cephapirin bound to human serum proteins is less than that of cephalothin similarly bound (3). Seventeen children responded "satisfactorily" to cephapirin treatment of pneumonia, lung abscess, and urinary-tract and soft-tissue infections (4).
Six patients undergoing chronic hemodialysis and 10 patients with chronic renal insufficiency hospitalized for nondialytic therapy received 1.0 g of cephapirin sodium by the intravenous route. The concentrations of cephapirin in arterial and venous plasma, dialysate, venous blood, and urine were measured during the ensuing 6 hr. The serum half-life of cephapirin was 105 to 108 min for the dialyzed patients and 95.9 min for the nondialyzed patients. Dialysis removed 22.8% of the administered dose. Nondialyzed patients excreted 19.5 % of the administered dose in the urine. The concentration of cephapirin in the urine of all nondialyzed patients exceeded 50,ug/ml. The recovery of cephapirin in the urine collected for 6 hr after injection was from 34 to 770 mg (mean 195 mg). To maintain a concentration of cephapirin in the blood and urine which exceeds the minimal inhibitory concentration for most gram-positive and gram-negative microorganisms, nondialyzed patients should receive 15 to 18 mg of cephapirin per kg every 12 hr. Dialyzed patients should receive the same dose just prior to dialysis and every 12 hr thereafter.
Cephapirin, 7-(pyrid-4-yl thioacetamido) cephalosporonate, is a new semisynthetic derivative of 7-aminocephalosporanic acid effective in vitro against gram-positive and gram-negative microorganisms. Concentrations of cephapirin necessary to inhibit Diplococcus pneumoniae, Mycobacterium tuberculosis (H37Rv), and Enterobacter sp. in vivo are less than those of cephalothin (3) . The amount of cephapirin bound to human serum proteins is less than that of cephalothin similarly bound (3). Seventeen children responded "satisfactorily" to cephapirin treatment of pneumonia, lung abscess, and urinary-tract and soft-tissue infections (4) .
This report describes the clearance of cephapirin from the blood during hemodialysis and the urinary excretion of intravenously administered cephapirin during nondialytic treatment of azotemia.
MATERIALS AND METHODS Patient population. Of the 16 azotemic patients who participated in the study, 10 were hospitalized for nondialytic therapy of chronic renal failure and 6 were undergoing extracorporal hemodialysis two times weekly in anticipation of renal transplantation. The mean serum creatinine of the dialyzed patients was 13.1 mg/100 ml; that of the nondialyzed patients was 90 6.6 mg/100 ml. Hemodialysis lasted 6 hr and was performed by use of a twin-coil Travenol RSP dialyzer with a Visking UF 145 membrane. Each patient received 1.0 g of cephapirin sodium intravenously over a period of 5 min. From the six patients who underwent dialysis, venous blood, arterial blood, and dialysate were obtained 0. 5, 1, 2, 3, 4, 6, 7, 8, 9 , and 48 hr after cephapirin was injected. Venous blood and urine were obtained from the 10 nondialyzed patients 0.5, 1, 2, 4, and 6 hr after the injection of 1.0 g of cephapirin sodium.
Cephapirin concentration. Serum or plasma was diluted with an equal volume of acetone-buffer (50% acetone-50% pH 6.0 phosphate buffer, v/v) and centrifuged at 2,000 rev/min for 10 min to remove precipitated protein. Urine samples were diluted with pH 6.0 phosphate buffer. Serum and urine were assayed immediately by the agar plate bioassay method (5). Sarcina lutea (ATCC 9341) was incubated at 32 C for 18 hr, and was diluted so that a 10% suspension produced 20%O light transmission at 580 nm. This suspension was the inoculum for all assays. The diameter of the inhibition zone surrounding each unknown sample was measured, and the cephapirin concentration was determined by comparison with a standard curve relating reference cephapirin concentrations (0.1 to 0.5 ,ug/ml) to zone of inhibition produced by the reference concentration. Reference concentrations of cephapirin were included with each assay of experimental serum, plasma, or urine.
RESULTS
Dialyzed patients. The mean serum half-time (Tf) in venous plasma was 108 min (98 to 118 min). The Tyf in arterial plasma was 105 min. Inspection of Fig. 1 and 2 shows that throughout dialysis a concentration of cephapirin was maintained which exceeded the minimal inhibiting concentration (MIC) for group A streptococci, D. pneumoniae, penicillin-susceptible and penicillin- 
where A is the arterial plasma concentration of cephapirin (,ug/ml), V is the venous plasma concentration of cephapirin (,g/ml), D is the dialysate concentration of cephapirin (,ug/ml), and F is the blood flow through the dialyzer (ml/min). Figure 3 shows the relationship of T'.W in venous blood serum to serum creatinine at the beginning of the study period. Over a range of serum creatinine from 1.5 to 11.5, the Tl' value increased only 40 min (90 to 130 min). The regression curve in Fig. 3 can be used to predict Tjt when the serum creatinine is known, assuming that dosage and serum concentration are as found on an average in this report. During the 6 hr after injection of cephapirin sodium, concentrations of the antibiotics were maintained at levels exceeding the MIC for most gram-positive and gram-negative organisms with the exception of some strains of indole-positive Proteus sp. and Enterobacter sp. The decline of serum cephapirin concentrations with elapsed time after injection is shown in Fig. 4 . Curves indicating the cephapirin concentrations from sera of individual patients with the lowest and highest creatinine values display the prolongation of T' ! as the serum creati- (6) .
The serum creatinine was most closely correlated with the serum T½ of cephapirin, and can be used to predict the serum Tkf in nondialyzed patients (Fig. 3) . The serum creatinine determination is available essentially to all physicians attending patients with renal insufficiency and provides a reliable method for estimating Tj., (2, 8) .
Administration of 15 to 18 mg of cephapirin sodium per kg every 8 to 12 hr should provide effective therapeutic concentrations in the serum and urine. Other investigators have recommended shorter dose intervals for treatment of urinarytract infections (C. E. Cox and W. W. King, Abstr. Intersci. Conf. Antimicrob. Ag. Chemother., 11th, Atlantic City, N.J., 1971).
Cephapirin, like cephalothin and cephaloridine (7, 9) , is removed from the blood by hemodialysis. Extrapolation of the free antibiotic concentration curve in blood after dialysis (Fig. 2) indicates that a dose of 15 to 18 mg of cephapirin per kg just before dialysis would result in concentrations below the MIC for some gram-negative bacteria 12 hr after injection of the drug. Within 48 hr, no antibiotic was present in the blood. These data indicate that 15 to 18 mg of cephapirin sodium per kg should be given just prior to dialysis and every 12 hr thereafter if free antibiotic concentrations in plasma exceeding 10 ,ug/ml are to be maintained.
